Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 121 AL 135

Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease

Supnet C, Bezprozvanny I.

J Alzheimers Dis. 2010;20 Suppl 2(Suppl 2):S487-98. doi: 10.3233/JAD-2010-100306.

Lipids and cognition

Morley JE, Banks WA.

J Alzheimers Dis. 2010;20(3):737-47. doi: 10.3233/JAD-2010-091576.

Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis

Mondragón-Rodríguez S, Basurto-Islas G, Lee HG, Perry G, Zhu X, Castellani RJ, Smith MA.

Expert Rev Neurother. 2010 May;10(5):683-91. doi: 10.1586/ern.10.27.

Current therapeutic targets for the treatment of Alzheimer's disease

Grill JD, Cummings JL.

Expert Rev Neurother. 2010 May;10(5):711-28. doi: 10.1586/ern.10.29.

Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents

Darvesh AS, Carroll RT, Bishayee A, Geldenhuys WJ, Van der Schyf CJ.

Expert Rev Neurother. 2010 May;10(5):729-45. doi: 10.1586/ern.10.42.

Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease

Dumont M, Lin MT, Beal MF.

J Alzheimers Dis. 2010;20 Suppl 2(Suppl 2):S633-43. doi: 10.3233/JAD-2010-100507.

Alzheimer's disease: strategies for disease modification

Citron M.

Nat Rev Drug Discov. 2010 May;9(5):387-98. doi: 10.1038/nrd2896.

Gelsolin as therapeutic target in Alzheimer's disease

Carro E.

Expert Opin Ther Targets. 2010 Jun;14(6):585-92. doi: 10.1517/14728222.2010.488222.

[Possibilities of preventive treatment of Alzheimer's disease: results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly patients with the syndrome of mild cognitive impairment]

Gavrilova SI, Kolykhalov IV, Fedorova IaB, Selezneva ND, Kalyn IaB, Roshchina IF, Odinak MM, Emelin AIu, Kashin AV, Gustov AV, Antipenko EA, Korshunova IuA, Davydova TA, Messler G.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):62-9.

Membrane biophysics and mechanics in Alzheimer's disease

Yang X, Askarova S, Lee JC.

Mol Neurobiol. 2010 Jun;41(2-3):138-48. doi: 10.1007/s12035-010-8121-9. Epub 2010 May 1.

Putative neuroprotective effects of caffeine in clinical trials. Concluding remarks

de Mendonça A, Cunha RA.

J Alzheimers Dis. 2010;20 Suppl 1:S249-52. doi: 10.3233/JAD-2010-01411.

Targeting tau protein in Alzheimer's disease

Gong CX, Grundke-Iqbal I, Iqbal K.

Drugs Aging. 2010 May;27(5):351-65. doi: 10.2165/11536110-000000000-00000.

Cholesterol, Alzheimer's disease, prion disorders: a ménage à trois?

Pani A, Mandas A, Dessì S.

Curr Drug Targets. 2010 Aug;11(8):1018-31. doi: 10.2174/138945010791591386.

Beyond the signaling effect role of amyloid-ß42 on the processing of APP, and its clinical implications

Lahiri DK, Maloney B.

Exp Neurol. 2010 Sep;225(1):51-4. doi: 10.1016/j.expneurol.2010.04.018. Epub 2010 May 5.

Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease

McGeown WJ, Shanks MF, Forbes-McKay KE, Waiter GD, Elrick I, Venneri MG, Venneri A.

Curr Alzheimer Res. 2010 Aug;7(5):415-27. doi: 10.2174/156720510791383877.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias